Ekso Bionics (EKSO) Stock Forecast, Price Target & Predictions
EKSO Stock Forecast
Ekso Bionics stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
EKSO Analyst Ratings
According to 1 Wall Street analysts, Ekso Bionics's rating consensus is 'Buy'. The analyst rating breakdown for EKSO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 24, 2024 | Lake Street | - | Buy | Initialise |
Ekso Bionics's last stock rating was published by Lake Street on Jun 24, 2024. The company Initialise its EKSO rating from "null" to "Buy".
Ekso Bionics Financial Forecast
Ekso Bionics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $4.70M | $4.12M | $3.55M | $3.33M | - | $2.57M | $4.08M | $3.05M | $2.21M | $1.91M | $2.25M | $2.90M | $2.26M | $1.47M | $3.72M | $3.32M | $3.26M | $3.62M | $3.30M | $2.55M |
| Avg Forecast | $8.70M | $7.80M | $6.25M | $5.05M | $6.05M | $5.55M | $5.15M | $5.00M | $4.80M | $4.50M | $4.40M | $2.80M | $3.94M | $3.58M | $3.49M | $3.20M | $2.76M | $2.58M | $2.14M | $3.00M | $2.58M | $2.45M | $1.62M | $1.41M | $3.65M | $3.15M | $4.24M | $3.90M | $2.81M | $2.10M |
| High Forecast | $9.41M | $8.43M | $6.76M | $5.46M | $6.54M | $6.00M | $5.57M | $5.41M | $5.19M | $4.86M | $4.76M | $3.03M | $4.26M | $3.87M | $3.49M | $3.20M | $2.76M | $2.58M | $2.14M | $3.00M | $2.58M | $2.45M | $1.62M | $1.41M | $3.65M | $3.15M | $4.24M | $3.90M | $3.37M | $2.52M |
| Low Forecast | $7.99M | $7.17M | $5.74M | $4.64M | $5.56M | $5.10M | $4.73M | $4.59M | $4.41M | $4.14M | $4.04M | $2.57M | $3.62M | $3.29M | $3.49M | $3.20M | $2.76M | $2.58M | $2.14M | $3.00M | $2.58M | $2.45M | $1.62M | $1.41M | $3.65M | $3.15M | $4.24M | $3.90M | $2.25M | $1.68M |
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.47% | 0.90% | 0.93% | - | 0.80% | 1.48% | 1.18% | 1.03% | 0.64% | 0.87% | 1.18% | 1.40% | 1.04% | 1.02% | 1.05% | 0.77% | 0.93% | 1.17% | 1.21% |
Ekso Bionics's average Quarter revenue forecast for Sep 23 based on 0 analysts is $4.50M, with a low forecast of $4.14M, and a high forecast of $4.86M. EKSO's average Quarter revenue forecast represents a -4.32% decrease compared to the company's last Quarter revenue of $4.70M (Jun 23).
Ekso Bionics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-4.28M | $-4.04M | $-4.47M | $-3.48M | - | $-4.36M | $-2.70M | $-1.78M | $-1.10M | $-3.52M | $-3.79M | $2.62M | $-11.57M | $-2.32M | $-2.48M | $320.00K | $-2.71M | $-6.18M | $-3.66M | $-6.55M |
| Avg Forecast | $-8.24M | $-7.38M | $-5.92M | $-4.78M | $-5.73M | $-5.25M | $-4.88M | $-6.06M | $-4.54M | $-4.26M | $-4.17M | $-5.51M | $-3.73M | $-2.97M | $-3.31M | $-5.01M | $-2.91M | $-2.34M | $-1.06M | $-2.26M | $-1.67M | $-2.32M | $-15.71M | $-2.96M | $-2.67M | $587.31K | $-3.66M | $-4.64M | $-3.02M | $-5.15M |
| High Forecast | $-7.57M | $-6.79M | $-5.44M | $-4.39M | $-5.26M | $-4.83M | $-4.48M | $-4.85M | $-4.18M | $-3.92M | $-3.83M | $-4.41M | $-3.42M | $-2.37M | $-3.31M | $-4.00M | $-2.33M | $-1.88M | $-844.03K | $-1.81M | $-1.34M | $-2.32M | $-12.56M | $-2.37M | $-2.14M | $704.77K | $-2.93M | $-3.71M | $-2.42M | $-4.12M |
| Low Forecast | $-8.90M | $-7.98M | $-6.40M | $-5.17M | $-6.19M | $-5.68M | $-5.27M | $-7.27M | $-4.91M | $-4.61M | $-4.50M | $-6.61M | $-4.03M | $-3.56M | $-3.31M | $-6.01M | $-3.50M | $-2.81M | $-1.27M | $-2.71M | $-2.00M | $-2.32M | $-18.85M | $-3.56M | $-3.21M | $469.85K | $-4.40M | $-5.56M | $-3.63M | $-6.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.73% | 1.20% | 1.17% | - | 0.87% | 0.93% | 0.76% | 1.04% | 1.56% | 2.27% | -1.13% | 0.74% | 0.78% | 0.93% | 0.54% | 0.74% | 1.33% | 1.21% | 1.27% |
10 analysts predict EKSO's average Quarter EBITDA for Dec 20 to be $-1.67M, with a high of $-1.34M and a low of $-2.00M. This is -163.73% lower than Ekso Bionics's previous annual EBITDA (Sep 20) of $2.62M.
Ekso Bionics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-4.23M | $-4.20M | $-2.05M | $-4.95M | - | $-5.00M | $-2.90M | $-1.96M | $-1.27M | $-3.67M | $-3.98M | $2.45M | $-11.77M | $-2.53M | $-2.72M | $206.00K | $-3.07M | $-6.55M | $-4.13M | $-6.98M |
| Avg Forecast | $-91.12K | $-546.72K | $-1.37M | $-1.91M | $-1.55M | $-1.91M | $-2.37M | $-6.27M | $-2.00M | $-5.65M | $-5.10M | $-5.70M | $-4.01M | $-3.27M | $-4.18M | $-5.18M | $-3.09M | $-2.58M | $-1.22M | $-2.35M | $-1.75M | $6.11M | $-15.97M | $-3.24M | $-2.93M | $378.08K | $-4.14M | $-4.91M | $-3.41M | $-5.49M |
| High Forecast | $-81.52K | $-489.09K | $-1.22M | $-1.71M | $-1.39M | $-1.71M | $-2.12M | $-5.02M | $-1.79M | $-5.05M | $-4.56M | $-4.56M | $-3.59M | $-2.62M | $-4.18M | $-4.15M | $-2.47M | $-2.07M | $-977.66K | $-1.88M | $-1.40M | $7.33M | $-12.78M | $-2.59M | $-2.34M | $453.70K | $-3.31M | $-3.93M | $-2.73M | $-4.40M |
| Low Forecast | $-100.72K | $-604.35K | $-1.51M | $-2.12M | $-1.71M | $-2.12M | $-2.62M | $-7.53M | $-2.22M | $-6.25M | $-5.64M | $-6.84M | $-4.43M | $-3.92M | $-4.18M | $-6.22M | $-3.71M | $-3.10M | $-1.47M | $-2.83M | $-2.10M | $4.89M | $-19.16M | $-3.89M | $-3.52M | $302.46K | $-4.97M | $-5.90M | $-4.10M | $-6.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.83% | 0.74% | 0.51% | 1.52% | - | 0.97% | 0.94% | 0.76% | 1.04% | 1.56% | 2.27% | 0.40% | 0.74% | 0.78% | 0.93% | 0.54% | 0.74% | 1.33% | 1.21% | 1.27% |
Ekso Bionics's average Quarter net income forecast for Dec 20 is $-1.75M, with a range of $-2.10M to $-1.40M. EKSO's average Quarter net income forecast represents a -171.35% decrease compared to the company's last Quarter net income of $2.45M (Sep 20).
Ekso Bionics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $5.14M | $5.29M | $5.17M | $4.40M | - | $4.45M | $6.15M | $3.98M | $3.93M | $3.77M | $3.65M | $3.45M | $3.65M | $4.71M | $4.11M | $4.41M | $5.16M | $5.13M | $5.29M | $5.89M |
| Avg Forecast | $12.41M | $11.12M | $8.91M | $7.20M | $8.63M | $7.91M | $7.34M | $7.13M | $6.85M | $6.42M | $6.27M | $3.99M | $5.61M | $5.11M | $4.98M | $4.56M | $3.94M | $3.67M | $3.05M | $2.42M | $1.60M | $3.49M | $2.31M | $2.01M | $5.20M | $4.50M | $6.05M | $3.84M | $4.00M | $3.00M |
| High Forecast | $13.41M | $12.03M | $9.64M | $7.79M | $9.33M | $8.56M | $7.94M | $7.71M | $7.40M | $6.94M | $6.78M | $4.32M | $6.07M | $5.52M | $4.98M | $4.56M | $3.94M | $3.67M | $3.05M | $2.90M | $1.93M | $3.49M | $2.31M | $2.01M | $5.20M | $4.50M | $6.05M | $4.61M | $4.80M | $3.60M |
| Low Forecast | $11.40M | $10.22M | $8.19M | $6.62M | $7.93M | $7.27M | $6.75M | $6.55M | $6.29M | $5.90M | $5.77M | $3.67M | $5.16M | $4.70M | $4.98M | $4.56M | $3.94M | $3.67M | $3.05M | $1.94M | $1.28M | $3.49M | $2.31M | $2.01M | $5.20M | $4.50M | $6.05M | $3.08M | $3.20M | $2.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.82% | 1.33% | 0.92% | 0.86% | - | 0.97% | 1.56% | 1.08% | 1.29% | 1.56% | 2.27% | 0.99% | 1.58% | 2.35% | 0.79% | 0.98% | 0.85% | 1.33% | 1.32% | 1.97% |
Ekso Bionics's average Quarter SG&A projection for Sep 23 is $6.42M, based on 0 Wall Street analysts, with a range of $5.90M to $6.94M. The forecast indicates a 24.85% rise compared to EKSO last annual SG&A of $5.14M (Jun 23).
Ekso Bionics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.31 | $-0.32 | $-0.16 | $-0.38 | - | $-0.39 | $-0.23 | $-0.15 | $-0.10 | $-0.34 | $-0.55 | $0.30 | $-1.88 | $-0.44 | $-0.53 | $0.04 | $-0.65 | $-1.51 | $-0.99 | $-1.71 |
| Avg Forecast | $-0.01 | $-0.03 | $-0.07 | $-0.10 | $-0.09 | $-0.10 | $-0.13 | $-0.16 | $-0.11 | $-0.31 | $-0.28 | $-0.31 | $-0.22 | $-0.24 | $-0.24 | $-0.41 | $-0.25 | $-0.25 | $-0.25 | $-0.24 | $-0.30 | $-0.39 | $-0.56 | $-0.61 | $-0.65 | $-1.05 | $-1.20 | $-1.20 | $-0.95 | $-1.07 |
| High Forecast | $-0.00 | $-0.03 | $-0.07 | $-0.09 | $-0.08 | $-0.09 | $-0.12 | $-0.14 | $-0.10 | $-0.28 | $-0.25 | $-0.28 | $-0.20 | $-0.21 | $-0.24 | $-0.41 | $-0.25 | $-0.25 | $-0.25 | $-0.24 | $-0.30 | $-0.39 | $-0.56 | $-0.61 | $-0.65 | $-1.05 | $-1.20 | $-1.20 | $-0.76 | $-0.86 |
| Low Forecast | $-0.01 | $-0.03 | $-0.08 | $-0.12 | $-0.09 | $-0.12 | $-0.14 | $-0.18 | $-0.12 | $-0.34 | $-0.31 | $-0.34 | $-0.24 | $-0.27 | $-0.24 | $-0.41 | $-0.25 | $-0.25 | $-0.25 | $-0.24 | $-0.30 | $-0.39 | $-0.56 | $-0.61 | $-0.65 | $-1.05 | $-1.20 | $-1.20 | $-1.14 | $-1.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.11% | 1.03% | 0.73% | 1.58% | - | 0.95% | 0.92% | 0.60% | 0.40% | 1.42% | 1.83% | -0.77% | 3.39% | 0.72% | 0.82% | -0.04% | 0.54% | 1.26% | 1.04% | 1.60% |
According to 10 Wall Street analysts, Ekso Bionics's projected average Quarter EPS for Dec 20 is $-0.30, with a low estimate of $-0.30 and a high estimate of $-0.30. This represents a -200.00% decrease compared to EKSO previous annual EPS of $0.30 (Sep 20).
EKSO Forecast FAQ
Is Ekso Bionics a good buy?
Yes, according to 1 Wall Street analysts, Ekso Bionics (EKSO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of EKSO's total ratings.
What are Ekso Bionics's analysts' financial forecasts?
Ekso Bionics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $21.75M (high $23.51M, low $19.99M), average EBITDA is $-21.916M (high $-19.419M, low $-24.413M), average net income is $-12.104M (high $-10.235M, low $-13.973M), average SG&A $31.02M (high $33.53M, low $28.5M), and average EPS is $-0.48 (high $-0.429, low $-0.531). EKSO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $27.8M (high $30.05M, low $25.55M), average EBITDA is $-26.32M (high $-24.186M, low $-28.454M), average net income is $-3.918M (high $-3.505M, low $-4.331M), average SG&A $39.64M (high $42.86M, low $36.43M), and average EPS is $-0.215 (high $-0.192, low $-0.238).
Did the EKSO's actual financial results beat the analysts' financial forecasts?
Based on Ekso Bionics's last annual report (Dec 2022), the company's revenue was $12.91M, which missed the average analysts forecast of $14.21M by -9.15%. Apple's EBITDA was $-15.586M, beating the average prediction of $-15.006M by 3.86%. The company's net income was $-14.604M, missing the average estimation of $-16.643M by -12.25%. Apple's SG&A was $18.14M, missing the average forecast of $20.27M by -10.48%. Lastly, the company's EPS was $-1.13, beating the average prediction of $-1.11 by 1.80%. In terms of the last quarterly report (Jun 2023), Ekso Bionics's revenue was $4.7M, beating the average analysts' forecast of $4.4M by 6.89%. The company's EBITDA was $-4.284M, beating the average prediction of $-4.166M by 2.84%. Ekso Bionics's net income was $-4.23M, missing the average estimation of $-5.103M by -17.10%. The company's SG&A was $5.14M, missing the average forecast of $6.27M by -18.08%. Lastly, the company's EPS was $-0.31, beating the average prediction of $-0.28 by 10.71%